ImmunoForge is a clinical-stage, VC-backed company specializing in novel drug development based on ELP platform technology, powered by world-class expertise and focusing initially on muscular dystrophies such as Polymyositis (PM), Dermatomyositis (DM), Duchenne muscular dystrophy (DMD), Inclusion Body Myositis (IBM) and Senile Sarcopenia. ImmunoForge has an ongoing Phase 2 clinical study for its lead drug candidate PF1801 (froniglutide) for treatment of DM/PM in Korea, and has received orphan drug designation from US FDA for use of PF1801 for treatment of PM, DM and DMD. ImmunoForge is further exploiting its ELP platform technology to enable weekly injection of peptide-based drugs for DMD cardiomyopathy, achondroplasia and short bowel syndrome, and is looking for co-development or licensing partners to bring its drug candidates to market. ImmunoForge is also developing KF1601, an NCE for treatment of drug-resistant CML, including the most common resistant mutant form, BCR-ABLT315I.